PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-90.13%
Revenue decline while RVPH shows 0.00% growth. Joel Greenblatt would examine competitive position erosion.
No Data
No Data available this quarter, please select a different quarter.
-148.93%
Gross profit decline while RVPH shows 0.00% growth. Joel Greenblatt would examine competitive position.
-595.65%
Margin decline while RVPH shows 0.00% expansion. Joel Greenblatt would examine competitive position.
15.04%
R&D growth less than half of RVPH's 87.08%. David Dodd would verify if efficiency advantage is sustainable.
33.15%
G&A growth 1.25-1.5x RVPH's 23.58%. Martin Whitman would scrutinize overhead control.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.43%
Operating expenses growth less than half of RVPH's 60.07%. David Dodd would verify sustainability.
20.43%
Total costs growth less than half of RVPH's 60.07%. David Dodd would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
3.01%
D&A growth less than half of RVPH's 407.91%. David Dodd would verify if efficiency is sustainable.
-24.86%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
-1164.87%
EBITDA margin decline while RVPH shows 0.00% growth. Joel Greenblatt would examine position.
-24.41%
Both companies show declining income. Martin Whitman would check industry conditions.
-1160.31%
Operating margin decline while RVPH shows 0.00% growth. Joel Greenblatt would examine position.
-17.39%
Other expenses reduction while RVPH shows 38.89% growth. Joel Greenblatt would examine advantage.
-24.71%
Both companies show declining income. Martin Whitman would check industry conditions.
-1163.35%
Pre-tax margin decline while RVPH shows 0.00% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-24.71%
Both companies show declining income. Martin Whitman would check industry conditions.
-1163.35%
Net margin decline while RVPH shows 0.00% growth. Joel Greenblatt would examine position.
-23.33%
Both companies show declining EPS. Martin Whitman would check industry conditions.
-23.33%
Both companies show declining diluted EPS. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.